Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

Rhea-AI Summary

Apimeds Pharmaceuticals US (NYSE American: APUS) has successfully completed its Initial Public Offering (IPO), raising $13.5 million in gross proceeds through the sale of 3,375,000 common stock shares at $4.00 per share. The company's shares began trading on NYSE American under the symbol "APUS" on May 9, 2025.

The clinical-stage biopharmaceutical company is developing Apitox, an intradermally administered bee venom-based toxin with potential therapeutic applications. The IPO proceeds will fund a Phase III clinical trial in knee osteoarthritis, initiate corporate sponsorship studies in multiple sclerosis, support product manufacturing, and address working capital needs.

D. Boral Capital served as the sole book-running manager, with underwriters receiving a 45-day option to purchase up to 506,250 additional shares and warrants for up to 168,750 shares.

Positive

• Successfully raised $13.5 million in gross proceeds through IPO
• Phase III clinical trial stage indicates advanced development progress
• Diverse therapeutic applications potential across multiple conditions
• Clear allocation of funds for clinical trials and product manufacturing

Negative

• Potential dilution from additional share options granted to underwriters
• Early-stage company with no approved products yet
• Significant capital requirements for clinical trials and manufacturing
• Competition in both osteoarthritis and multiple sclerosis markets

Insights

IPO Financial Analyst

Apimeds has successfully raised $13.5M via IPO at $4/share to fund critical Phase III trials for bee venom-based therapeutics.

Apimeds Pharmaceuticals has completed its initial public offering, raising $13.5 million in gross proceeds through the sale of 3,375,000 shares at $4.00 per share. The IPO represents a modest capital raise relative to typical biopharma offerings, reflecting the early-stage nature of the company's pipeline. Their shares began trading on the NYSE American exchange on May 9 under the ticker "APUS".

The IPO structure includes additional provisions that could increase capital: underwriters have a 45-day option to purchase an additional 506,250 shares, potentially increasing proceeds by approximately $2 million. The company also issued warrants to underwriters for up to 168,750 shares (or 194,063 if over-allotment exercised), exercisable after a 180-day lockup period.

The proceeds have clearly designated purposes, with the capital primarily allocated to fund a critical Phase III trial for knee osteoarthritis, initiate corporate sponsorship studies for multiple sclerosis applications, expand manufacturing capacity, and address working capital needs. This financing should provide Apimeds with runway to reach significant clinical milestones.

Notably, the company's lead candidate Apitox, an intradermally-administered bee venom-based toxin, represents an interesting therapeutic approach that could potentially address multiple indications. The advancement to Phase III trials for osteoarthritis suggests promising earlier clinical results, though investors should recognize that even with successful Phase III trials, commercialization remains distant and would require substantial additional capital beyond this initial raise.

Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.” 

Gross proceeds to Apimeds from the Offering were $13.5 million, before deducting underwriting discounts and commissions and other related expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option from the closing of the Offering to purchase up to an additional 506,250 shares of common stock at the public offering price, less underwriting discounts, and issued to the underwriters warrants to purchase up to a total of 168,750 shares of common stock (or 194,063 shares if the over-allotment option is exercised in full) exercisable during the four and a half-year period commencing 180 days from the closing of the Offering.

D. Boral Capital LLC  (“D. Boral”) acted as sole book-running manager for the Offering. D. Boral was represented by Blank Rome LLP, led by Brad Shiffman and Naomi Gallimore. Apimeds was represented by Nelson Mullins Riley & Scarborough LLP, led by David Mannheim, Mike Bradshaw and Kathryn Simons. 

The Company expects to use the net proceeds from the sale of the shares to fund a Phase III clinical trial in knee osteoarthritis, to initiate at least one non-registered corporate sponsorship study in multiple sclerosis, to manufacture its product candidate, and to address general working capital needs.

A registration statement on Form S-1 (File No. 333-282324) relating to the securities sold in the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on February 11, 2025. A post-effective amendment to the registration statement was filed with the SEC and declared effective on May 5, 2025. This Offering was made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, from: D. Boral Capital LLC, 590 Madison Ave., 39th Floor, New York, NY 10022, by telephone: (212) 970-5150, or by email at: info@dboralcapital.com. 

This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Apimeds Pharmaceuticals US, Inc.

Apimeds (NYSE American: APUS) is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who fail to respond adequately to conservative non-pharmacologic therapy and simple analgesics. For more information visit www.apimedsus.com.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” with respect to the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company’s future results may be materially different from and worse than what we expect. Copies are available on the SEC’s website, www.sec.gov. Other sections of the prospectus include additional factors which could adversely impact the Company’s business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company’s management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. 

You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the prospectus relate only to events or information as of the date on which the statements are made in the prospectus. Neither the Company nor the underwriters undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read the prospectus and the documents that we refer to in the prospectus and have filed as exhibits to the registration statement, of which the prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.

Contact:

Erik Emerson
Apimeds Pharmaceuticals US, Inc.
(808) 209-7887

FAQ

How much did Apimeds Pharmaceuticals (APUS) raise in its IPO?

Apimeds Pharmaceuticals raised $13.5 million in gross proceeds through its IPO by selling 3,375,000 shares at $4.00 per share.

What is APUS stock's main product candidate?

Apimeds' main product candidate is Apitox, an intradermally administered bee venom-based toxin being developed for therapeutic applications.

What will Apimeds (APUS) use its IPO proceeds for?

The proceeds will fund a Phase III trial in knee osteoarthritis, initiate multiple sclerosis studies, support product manufacturing, and address working capital needs.

When did APUS stock begin trading on NYSE American?

APUS shares began trading on the NYSE American on May 9, 2025.

What is the over-allotment option in Apimeds' IPO?

Underwriters received a 45-day option to purchase up to 506,250 additional shares at the public offering price, less underwriting discounts.